Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Eisai breast cancer drug shows efficacy in phase III trial

Eisai breast cancer drug shows efficacy in phase III trial

9th June 2010

Eisai has published new clinical data demonstrating the effectiveness of eribulin mesylate, its investigational treatment for breast cancer.

Results from the phase III Embrace trial show that eribulin mesylate demonstrated significantly improved rates of overall median survival among recurrent and metastatic breast cancer patients, when compared to alternative treatments chosen by physicians.

This means the drug met its overall efficacy endpoint, while encouraging results were also recorded in terms of the secondary objectives of progression free survival and overall response rate.

Eribulin mesylate is currently being considered for regulatory approval in a number of territories, including Europe, the US and Japan.

It is hoped that the treatment will help to combat metastatic breast cancer, with only one in five sufferers of the disease currently surviving for more than five years.

This data was presented at the American Society of Clinical Oncology annual meeting, where Eisai also highlighted trial data on new treatments for T-cell lymphoma and non-small cell lung cancer.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.